{"doc_id": "33406353", "type of study": "Therapy", "title": "", "abstract": "Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.\nTherapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive.\nAmong them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier in the course of illness.\nWe conducted a randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in older adult patients within 72 hours after the onset of mild Covid-19 symptoms.\nThe primary end point was severe respiratory disease, defined as a respiratory rate of 30 breaths per minute or more, an oxygen saturation of less than 93% while the patient was breathing ambient air, or both.\nThe trial was stopped early at 76% of its projected sample size because cases of Covid-19 in the trial region decreased considerably and steady enrollment of trial patients became virtually impossible.\nA total of 160 patients underwent randomization.\nIn the intention-to-treat population, severe respiratory disease developed in 13 of 80 patients (16%) who received convalescent plasma and 25 of 80 patients (31%) who received placebo (relative risk, 0.52; 95% confidence interval [CI], 0.29 to 0.94; P\u2009=\u20090.03), with a relative risk reduction of 48%.\nA modified intention-to-treat analysis that excluded 6 patients who had a primary end-point event before infusion of convalescent plasma or placebo showed a larger effect size (relative risk, 0.40; 95% CI, 0.20 to 0.81).\nNo solicited adverse events were observed.\nEarly administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults reduced the progression of Covid-19. (Funded by the Bill and Melinda Gates Foundation and the Fundaci\u00f3n INFANT Pandemic Fund; Direcci\u00f3n de Sangre y Medicina Transfusional del Ministerio de Salud number, PAEPCC19, Plataforma de Registro Informatizado de Investigaciones en Salud number, 1421, and ClinicalTrials.gov number, NCT04479163.).\nCopyright \u00a9 2021 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "Severe Covid-19", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 58}, {"term": "Older Adults", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 74}, {"term": "older adult", "negation": "affirmed", "UMLS": {}, "start": 186, "end": 197}, {"term": "respiratory rate of 30 breaths per minute or more", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 117}, {"term": "oxygen saturation of less than 93 %", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 158}, {"term": "mildly ill infected older adults", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 109}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults .", "Evidence Elements": {"Participant": [{"term": "Severe Covid-19", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 58}, {"term": "Older Adults", "negation": "affirmed", "UMLS": {}, "start": 62, "end": 74}], "Intervention": [{"term": "Early High-Titer Plasma Therapy", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 31}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Therapies to interrupt the progression of early coronavirus disease 2019 ( Covid-19 ) remain elusive .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Among them , convalescent plasma administered to hospitalized patients has been unsuccessful , perhaps because antibodies should be administered earlier in the course of illness .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "convalescent", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 25}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We conducted a randomized , double-blind , placebo-controlled trial of convalescent plasma with high IgG titers against severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) in older adult patients within 72 hours after the onset of mild Covid-19 symptoms .", "Evidence Elements": {"Participant": [{"term": "older adult", "negation": "affirmed", "UMLS": {}, "start": 186, "end": 197}], "Intervention": [{"term": "convalescent plasma with high IgG titers against severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 )", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 182}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary end point was severe respiratory disease , defined as a respiratory rate of 30 breaths per minute or more , an oxygen saturation of less than 93 % while the patient was breathing ambient air , or both .", "Evidence Elements": {"Participant": [{"term": "respiratory rate of 30 breaths per minute or more", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 117}, {"term": "oxygen saturation of less than 93 %", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 158}], "Intervention": [], "Outcome": [{"term": "severe respiratory disease", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 52}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The trial was stopped early at 76 % of its projected sample size because cases of Covid-19 in the trial region decreased considerably and steady enrollment of trial patients became virtually impossible .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "A total of 160 patients underwent randomization .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "In the intention-to-treat population , severe respiratory disease developed in 13 of 80 patients ( 16 % ) who received convalescent plasma and 25 of 80 patients ( 31 % ) who received placebo ( relative risk , 0.52 ; 95 % confidence interval [ CI ] , 0.29 to 0.94 ; P=0.03 ) , with a relative risk reduction of 48 % .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "convalescent plasma", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 138}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 183, "end": 190}], "Outcome": [{"term": "severe respiratory disease", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 65}], "Observation": [], "Count": [{"term": "13 of 80 patients ( 16 % )", "negation": "affirmed", "UMLS": {}, "start": 79, "end": 105}, {"term": "25 of 80 patients ( 31 % )", "negation": "affirmed", "UMLS": {}, "start": 143, "end": 169}]}, "Evidence Propositions": [{"Intervention": "convalescent plasma", "Observation": "", "Count": "13 of 80 patients ( 16 % )", "Outcome": "severe respiratory disease"}, {"Intervention": "placebo", "Observation": "", "Count": "25 of 80 patients ( 31 % )", "Outcome": "severe respiratory disease"}]}, {"Section": "RESULTS", "Text": "A modified intention-to-treat analysis that excluded 6 patients who had a primary end-point event before infusion of convalescent plasma or placebo showed a larger effect size ( relative risk , 0.40 ; 95 % CI , 0.20 to 0.81 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "convalescent plasma", "negation": "affirmed", "UMLS": {}, "start": 117, "end": 136}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 140, "end": 147}], "Outcome": [{"term": "primary end-point event", "negation": "affirmed", "UMLS": {}, "start": 74, "end": 97}, {"term": "effect size", "negation": "affirmed", "UMLS": {}, "start": 164, "end": 175}], "Observation": [{"term": "larger", "negation": "affirmed", "UMLS": {}, "start": 157, "end": 163}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "No solicited adverse events were observed .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "solicited adverse events", "negation": "negated", "UMLS": {}, "start": 3, "end": 27}], "Observation": [], "Count": [{"term": "No", "negation": "negated", "UMLS": {}, "start": 0, "end": 2}]}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults reduced the progression of Covid-19 . ( Funded by the Bill and Melinda Gates Foundation and the Fundaci\u00f3n INFANT Pandemic Fund ; Direcci\u00f3n de Sangre y Medicina Transfusional del Ministerio de Salud number , PAEPCC19 , Plataforma de Registro Informatizado de Investigaciones en Salud number , 1421 , and ClinicalTrials.gov number , NCT04479163 . ) .", "Evidence Elements": {"Participant": [{"term": "mildly ill infected older adults", "negation": "affirmed", "UMLS": {}, "start": 77, "end": 109}], "Intervention": [{"term": "high-titer convalescent plasma against SARS-CoV-2", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 73}], "Outcome": [{"term": "progression of Covid-19", "negation": "affirmed", "UMLS": {}, "start": 122, "end": 145}], "Observation": [{"term": "reduced", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 117}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}